What is Create Medicines?
CREATE Medicines is a clinical-stage biotechnology firm specializing in in vivo immune programming therapies. Leveraging its proprietary mRNA-LNP platform, the company engineers immune cells, including T cells, NK cells, and myeloid cells, directly inside the body. This innovative approach aims to create scalable, repeat-dose, off-the-shelf immunotherapies. The company's pipeline is focused on addressing oncology and autoimmune diseases through advanced RNA-based CAR approaches, designed to enhance patient accessibility and treatment programmability.
How much funding has Create Medicines raised?
Create Medicines has raised a total of $134M across 2 funding rounds:
Seed
$12M
Series B
$122M
Seed (2019): $12M, investors not publicly disclosed
Series B (2026): $122M led by Hatteras Venture Partners, ARCH Venture Partners, Newpath Partners, and Alexandria
Key Investors in Create Medicines
Hatteras Venture Partners
Hatteras Venture Partners is a venture capital firm dedicated to building transformative companies within the biotech, MedTech, and HealthTech sectors. They focus on investing in innovative healthcare solutions that offer therapeutic and diagnostic benefits, providing capital and strategic support to founders.
ARCH Venture Partners
ARCH Venture Partners is a prominent early-stage venture capital firm that focuses on creating and investing in life sciences and advanced technology companies. They frequently co-found startups with scientists and entrepreneurs to commercialize cutting-edge innovations.
Alexandria
Alexandria Real Estate Equities, Inc. is a real estate investment trust (REIT) that owns, operates, and develops properties for the life sciences industry. They provide essential laboratory and research facilities for pharmaceutical, biotechnology, and academic research entities.
What's next for Create Medicines?
The substantial enterprise-level capital infusion, highlighted by the recent strategic investment, positions CREATE Medicines for significant expansion and advancement of its therapeutic pipeline. This backing is likely to fuel further clinical trials, platform optimization, and potential strategic partnerships. The company's focus on programmable, in vivo immune cell engineering suggests a forward-looking strategy aimed at disrupting traditional cell therapy paradigms and addressing unmet needs in oncology and autoimmune disorders. Continued investment in this innovative modality signals strong confidence in its potential to deliver next-generation immunotherapies.
See full Create Medicines company page
